Japan Tardive Dyskinesia Therapeutics Market Insights Forecasts to 2033

• The Japan Tardive Dyskinesia Therapeutics Market Size was valued at USD 29.5 Million in 2023.
• The Market Size is Growing at a CAGR of 21.89% from 2023 to 2033
• The Japan Tardive Dyskinesia Therapeutics Market Size is Expected to Reach USD 213.5 Million by 2033

The Japan Tardive Dyskinesia Therapeutics Market is Anticipated to Exceed USD 213.5 Million by 2033, growing at a CAGR of 21.89% from 2023 to 2033. The growing patient population of mental disorders and rising consumption of antipsychotic drugs are driving the growth of the tardive dyskinesia therapeutics market in Japan.     

Market Overview

Tardive dyskinesia (TD) is a movement disorder that can develop as a potentially dangerous pharmacological reaction to a variety of psychiatric medicines, particularly antipsychotics. The development of TD is possible in individuals who have had treatment for schizophrenia, schizoaffective disorder, bipolar disorder, anxiety, or depression and who have taken or are currently taking psychotropic medications. Additionally, postmenopausal patients, who have a history of substance addiction, are 55 years of age or older, or suffer from a mental condition are more likely to develop TD. According to current data, between 20 and 30 percent of patients receiving long-term anti-psychotic medication went on to develop TD, demonstrating the condition's extensive impact. Valbenazine and deutetrabenazine are the two FDA-approved drugs used to manage the symptoms of Huntington's disease or tardive dyskinesia, out of which only valbenazine drugs had received approval from PMDA in Japan for the treatment. Further, dietary supplements, pharmaceutical therapies, and non-pharmacologic therapeutic modalities are also available in Japan as off-label treatments for this illness.

Report Coverage

This research report categorizes the market for the Japan tardive dyskinesia therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan tardive dyskinesia therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan tardive dyskinesia therapeutics market.

Driving Factors

In 2023, a cross-sectional study published by the Journal of Medical Investigation, found that among older persons in Japan, the prevalence of anxiety and depression was 43.9% and 69.4%, respectively. The rise in psychiatric diseases in Japan is responsible for driving the market as the increasing antipsychotic treatment among patients is likely to enhance the prevalence of tardive dyskinesia disease in Japan which ultimately leads to drive the market demand. Further, the rising prescription rate of antipsychotic medication among this patient population enhances their risk of tardive dyskinesia.

Restraining Factors

The lack of information about tardive dyskinesia among patients and healthcare providers as well as the limited treatment options are restraining the market for tardive dyskinesia therapeutics.

Market Segmentation

The Japan Tardive Dyskinesia Therapeutics Market share is classified into drug and distribution channel.

• The valbenazine segment dominated the market with the largest market share in 2023.

The Japan tardive dyskinesia therapeutics market is segmented by drug into deutetrabenazine, valbenazine, and others. Among these, the valbenazine segment dominated the market with the largest market share in 2023. Valbenazine is the only medication approved in Japan for the treatment of this condition. The manufacturers of valbenazines’s increasing emphasis on partnerships with domestic players in Japan as well as the inclusion in the National Health Insurance Drug Price List are expected to drive the market growth.

• The hospital pharmacies segment dominates the Japan tardive dyskinesia therapeutics market with the largest market share in 2023.       

Based on the distribution channel, the Japan tardive dyskinesia therapeutics market is divided into hospital pharmacies and retail pharmacies. Among these, the hospital pharmacies segment dominates the Japan tardive dyskinesia therapeutics market with the largest market share in 2023. The majority of Japan's supply of ethical medications is supplied by pharmaceutical manufacturers to wholesalers, who then distribute them to hospitals and clinics around the nation. The need to obtain prescription drugs for tardive dyskinesia from the hospital pharmacy is driving the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan tardive dyskinesia therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Teva Pharmaceutical Industries Ltd.
• Neurocrine Biosciences, Inc.
• Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation)
• Janssen Pharmaceutical K.K. (Johnson & Johnson Services, Inc.)
• SOM BIOTECH
• Luye Pharma Group
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In September 2023, Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for INGREZZA (valbenazine) oral granules, a new sprinkle formulation of INGREZZA (valbenazine) capsules for oral administration. 

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Japan Tardive Dyskinesia Therapeutics Market based on the below-mentioned segments:

Japan Tardive Dyskinesia Therapeutics Market, By Drug

• Deutetrabenazine
• Valbenazine
• Others

Japan Tardive Dyskinesia Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies